Crescent Biopharma
CBIO
55 hedge funds and large institutions have $61.9M invested in Crescent Biopharma in 2023 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 19 reducing their positions, and 8 closing their positions.
106% more call options, than puts
Call options by funds: $247K | Put options by funds: $120K
33% more capital invested
Capital invested by funds: $46.6M → $61.9M (+$15.3M)
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 54 → 55 (+1)
0.02% less ownership
Funds ownership: 0.58% → 0.55% (-0.02%)
68% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$226K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$119K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$90.7K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$50.3K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$42.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$691K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$423K |
| 3 |
Two Sigma Investments
New York
|
-$303K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$245K |
| 5 |
Two Sigma Advisers
New York
|
-$240K |
CBIO Hedge Fund Activity: Q2 2023 in Review
55 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q2 2023, worth a combined $61.9M — up 33% from $46.6M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new CBIO positions and 8 closed out — a net gain of 1 holder — while 6 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $226K. The largest seller was Millennium Management, cutting an estimated $691K.
- 55 institutional investors held Crescent Biopharma (CBIO) as of Q2 2023, up from 54 in Q1 2023.
- Funds reported $61.9M of Crescent Biopharma stock for Q2 2023, up 33% quarter-over-quarter.
- 9 funds opened new Crescent Biopharma positions in Q2 2023 and 8 closed out, a net change of +1 holder.
- The largest Crescent Biopharma buyer in Q2 2023 was BlackRock, an estimated $226K added.
- The largest Crescent Biopharma seller in Q2 2023 was Millennium Management, an estimated $691K sold.
Based on aggregated 13F filings for Q2 2023.